SCHEMBL1868286

SCHEMBL1868286

O=C(OC[C@H](O)[C@@H](O)COC(=O)c1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 1.00
PRKCA P17252 1/20 0.64
ADRB2 P07550 2/20 0.60
ADRB1 P08588 2/20 0.60
ADRB3 P13945 2/20 0.60
TDP1 Q9NUW8 2/20 0.59
MAPK1 P28482 1/20 0.57
HIF1A Q16665 1/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A3 Q01959 1/20 0.57
KMT2A Q03164 1/20 0.57
LMNA P02545 2/20 0.55
SLC1A5 Q15758 1/20 0.53
F2 P00734 1/20 0.52
TSHR P16473 3/20 0.52
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TP53 P04637 1/20 0.48
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8064782 1.00 ALDH1A1 (1.00) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL1862116 1.00 ALDH1A1 (1.00) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL1030284 1.00 ALDH1A1 (1.00) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL13625428 1.00 ALDH1A1 (1.00) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL23227764 0.92 ALDH1A1 (0.85) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL1030023 0.92 ALDH1A1 (0.85) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL1027311 0.92 ALDH1A1 (0.85) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL28825260 0.89 ALDH1A1 (0.79) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL28342950 0.89 ALDH1A1 (0.79) ALDH1A1PRKCAADRB2ADRB1ADRB3
SCHEMBL295042 0.88 ALDH1A1 (0.78) ALDH1A1PRKCAADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107835800-B Cyclic compound 武田药品工业株式会社 2019-11-26 CN disclosed
US-20180118708-A1 CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-03 US disclosed
EP-3294706-A1 CYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2018-03-21 EP disclosed
EP-3296296-A1 CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-03-21 EP disclosed
US-9828357-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-11-28 US disclosed
US-9611244-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-04 US disclosed
US-20170066737-A1 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 US disclosed
US-9533966-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-01-03 US disclosed
WO-2016182036-A1 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-17 WO disclosed
US-20160326102-A1 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-10 US disclosed
US-20160326133-A1 CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-11-10 US disclosed
EP-1935879-B1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-05-11 EP disclosed
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326102-A1 CYCLIC COMPOUNDS TLR4, TLR3, TLR1 ALDH1A1 698/4885PRKCA 904/4885ADRB2 2871/4885
US-20180118708-A1 CYCLIC COMPOUND TLR4, TLR3, TLR9 ALDH1A1 973/4885PRKCA 1046/4885ADRB2 3375/4885
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF ALDH1A1 4252/4885PRKCA 703/4885ADRB2 367/4885
US-20160326133-A1 CYCLIC COMPOUNDS TLR4, TLR3, TLR1 ALDH1A1 698/4885PRKCA 904/4885ADRB2 2871/4885
US-20170066737-A1 CYCLIC COMPOUNDS TLR4, TLR3, TLR1 ALDH1A1 668/4885PRKCA 830/4885ADRB2 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.